Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $889.5 million.

  • Amphastar Pharmaceuticals' Total Liabilities rose 880.44% to $889.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $889.5 million, marking a year-over-year increase of 880.44%. This contributed to the annual value of $845.2 million for FY2024, which is 324.2% down from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Total Liabilities is $889.5 million, which was up 880.44% from $857.9 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Total Liabilities peaked at $949.5 million during Q3 2023, and registered a low of $194.8 million during Q1 2021.
  • Its 5-year average for Total Liabilities is $554.7 million, with a median of $778.2 million in 2024.
  • In the last 5 years, Amphastar Pharmaceuticals' Total Liabilities surged by 32860.7% in 2023 and then plummeted by 1390.14% in 2024.
  • Over the past 5 years, Amphastar Pharmaceuticals' Total Liabilities (Quarter) stood at $226.0 million in 2021, then fell by 5.61% to $213.3 million in 2022, then skyrocketed by 309.46% to $873.5 million in 2023, then fell by 3.24% to $845.2 million in 2024, then grew by 5.24% to $889.5 million in 2025.
  • Its Total Liabilities was $889.5 million in Q3 2025, compared to $857.9 million in Q2 2025 and $875.0 million in Q1 2025.